Myopia Management for Children
Protecting Vision Today.
Safeguarding Eye Health for the Future.
Myopia (nearsightedness) is more than needing glasses. It is a condition where the eye grows longer than normal. As the eye length increases, prescriptions worsen and the lifetime risk of serious eye diseases rises.
At VODA Eyecare, we provide proactive, research-based myopia management designed to slow progression and support healthy eye development using advanced technology and personalized treatment plans.
FIRST VISIT
Complimentary First Screening
for Every Child
Every child seen for a myopia consultation receives a complimentary axial length measurement at their first visit.
Axial length is one of the most important indicators of myopia progression. Monitoring this measurement allows us to detect progression early — often before prescription changes are noticeable — and begin treatment at the optimal time. At VODA, we track axial length using the Topcon Myah, so we follow actual eye growth, not just prescription changes, and adjust your child's care plan accordingly.
The sooner progression is identified, the more effectively — and durably — it can be managed.
CLINICALLY PROVEN TREATMENT OPTIONS
Treatments Selected for
Safety and Effectiveness
We carefully select treatments supported by strong clinical evidence and regulatory approval. Every plan is built around your child's specific eyes — not a standard protocol.
ESSILOR STELLEST™
01
Advanced Spectacle Lens Technology
FDA-Authorized Myopia Control
If your child is nearsighted and getting worse every year, Stellest isn't just a stronger prescription. It's a treatment.
We're proud to offer Essilor Stellest™ — the first and only FDA-authorized spectacle lens clinically proven to slow the progression of myopia in children. Stellest lenses use Highly Aspherical Lenslet Technology (H.A.L.T.) — 1,021 nearly invisible lenslets arranged across 11 rings around a clear central zone. These lenslets create a precise volume of myopic defocus that signals the eye to slow its elongation — the structural change that drives worsening nearsightedness and increases lifetime risk of retinal and optic nerve complications.
H.A.L.T. TECHNOLOGY
1,021 lenslets. 11 rings.
One clear, powerful signal to slow eye growth.
Each lenslet creates a precise volume of myopic defocus in front of the retina — delivering a continuous therapeutic signal throughout the day while your child sees clearly through the central zone. The lenses look and wear exactly like any pair of glasses.
CLINICAL EVIDENCE
FDA-reviewed clinical trials | Children wearing Stellest full-time (10–12 hours/day). Six-year follow-up data available.
67%
less myopia progression
vs. single-vision lenses, full-time wear
53%
less axial elongation
slower eye growth vs. standard lenses
~2.00
diopters of myopia saved
over six years of treatment
6 yr
long-term follow-up
sustained effectiveness confirmed
Who It's For
Children ages 6–12 at the start of treatment experiencing myopia progression
Families who prefer spectacles over contact lenses — no handling, no drops, no complicated routines
Children with faster progression who need proven, early intervention
Any child where early treatment can meaningfully protect long-term vision
Monitored with axial length tracking. At VODA, Stellest treatment is paired with regular axial length monitoring using the Topcon Myah — so we follow actual eye growth, not just prescription changes, and adjust the plan as your child develops.
COOPERVISION MISIGHT® 1 DAY
02
Daily Disposable Contact Lenses
Proven Long-Term Results
MiSight is among the most extensively studied myopia treatments available — with long-term data spanning seven years showing sustained effectiveness, safety, and no significant rebound after stopping.
MiSight® 1 Day contact lenses are FDA-approved specifically for slowing myopia progression in children. Their dual-focus optical design corrects vision while simultaneously delivering therapeutic signals that help regulate eye growth — addressing both the symptom and the underlying structural progression.
Dual-Focus Design
Corrects vision in the central zone while myopic defocus rings signal the eye to slow elongation throughout the day.
Daily Disposable
Fresh lens every day — no cleaning, no storage, reduced infection risk. One of the safest contact modalities for children.
7-Year Data
The longest dataset of any myopia control contact lens — confirming sustained effectiveness and safety over the full treatment period.
No Rebound Effect
No significant rebound in myopia progression observed after stopping treatment — a key differentiator from some other therapies.
CLINICAL EVIDENCE
CooperVision MiSight® clinical program | Up to 7 years of follow-up data
59%
reduction in myopia progression
vs. single-vision daily disposables
52%
slowing of eye growth
axial elongation vs. control group
7 yr
sustained effectiveness confirmed
longest dataset for any myopia control CL
0
significant rebound effect
after discontinuing treatment
Who It's For
Children and teens ready for contact lens wear who prefer not to wear glasses full-time
Active children — sports, outdoor activities, or any situation where glasses are inconvenient
Patients where long-term safety data is a priority for the family
Children looking for a proven treatment with one of the strongest evidence bases available
PHARMACEUTICAL THERAPY
03
Low-Dose Atropine
for Faster Progression
For children whose myopia is advancing quickly, low-dose atropine provides an additional layer of control — especially when used alongside optical treatments.
Low-dose atropine eye drops may be prescribed when appropriate to help slow myopia progression. The mechanism is different from optical treatments — atropine works at a pharmacological level to reduce the signals that drive axial elongation. Used at low concentrations, side effects are minimal and well-tolerated by most children.
In children with faster progression, atropine is often combined with Stellest lenses or MiSight contacts to enhance overall effectiveness — addressing the condition from both optical and pharmaceutical angles simultaneously.
Who Benefits Most
Children with rapid myopia progression — increasing more than –0.75D per year
Younger children where early, aggressive management offers the most long-term benefit
Patients who have not achieved adequate control with optical treatment alone
As part of a combination approach alongside Stellest or MiSight
Most effective in combination. Atropine is rarely prescribed as a standalone treatment at VODA. It works best alongside optical treatments, and we monitor response closely with axial length measurements to confirm that the combined plan is producing real results.
PERSONALIZED PLANNING
04
Combination Therapy
Tailored to Each Child
Every child's eyes develop differently. Some respond best to a single treatment — others achieve the strongest results from a carefully designed combination plan.
Our goal is not just correction — it is controlled, healthy eye development. We customize each plan based on the full picture of your child's eyes and life.
Age
Younger children may benefit from earlier, more intensive intervention to protect the most critical years of eye development.
Prescription Level
Higher starting prescriptions may call for combination therapy to maximize slowing effect across multiple mechanisms.
Axial Length Growth
We track actual eye elongation, not just prescription — so treatment decisions are based on real structural data.
Family History
Parental myopia is a significant risk factor — we factor this into how proactively we approach early intervention.
Lifestyle & Visual Demands
Screen time, outdoor activity, sports, and learning environment all inform which treatment format fits best.
WHY SLOWING MYOPIA MATTERS
More Than a
Stronger Prescription
Higher levels of myopia are associated with increased lifetime risk of serious eye conditions. Slowing progression today helps reduce the likelihood of these complications later in life — and the earlier we start, the more vision we protect.
Glaucoma
Retinal detachment
Early cataracts
Myopic macular degeneration
THE VODA APPROACH
Education Is Part
of Treatment.
We take time to explain findings, answer questions, and partner with families — so parents feel confident and children feel comfortable throughout the process. Myopia management is not a one-size-fits-all solution. It is a carefully guided journey, tailored to each child, revisited at every visit.
This is the moment to act. Myopia that starts young tends to progress fast. The earlier we intervene, the more vision we protect.
SCHEDULE A MYOPIA CONSULTATION
Early Treatment Provides
the Strongest Protection.
Let us identify where your child's vision is today — and build a plan to protect where it's going.